2024
Osman, N., Curley, P., Box, H., Liptrott, N., Sexton, D., & Saleem, I. (2024). <i>In vitro</i> evaluation of physicochemical-dependent effects of polymeric nanoparticles on their cellular uptake and co-localization using pulmonary calu-3 cell lines.. Drug development and industrial pharmacy, 1-11. doi:10.1080/03639045.2024.2332889DOI: 10.1080/03639045.2024.2332889
Tatham, L., Sharp, J., Neary, M., Herriott, J., Kijak, E., Gallardo-Toledo, E., . . . Owen, A. (2024). Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1. Poster session presented at the meeting of The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024). Denver, US.
2023
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362DOI: 10.1093/jac/dkad362
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.. Viruses, 15(11), 2161. doi:10.3390/v15112161DOI: 10.3390/v15112161
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744DOI: 10.3390/v15081744
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823DOI: 10.1016/j.jchromb.2023.123823
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835DOI: 10.3390/pharmaceutics15071835
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. (Preprint)
DOI: 10.1101/2022.01.23.477397
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0DOI: 10.1038/s41586-022-05594-0
2022
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays. (Preprint)
DOI: 10.1101/2022.03.03.482788
2021
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1DOI: 10.26434/chemrxiv.13587035.v1
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035DOI: 10.26434/chemrxiv.13587035
2020
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1101/2020.05.01.20087130
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379DOI: 10.1101/2020.04.16.20068379
2019
Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529cDOI: 10.1039/c9na00529c
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726DOI: 10.1093/infdis/jiy726
Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies (Conference Paper)
Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Hobson, J., Al-Khouja, A., Curley, P., Meyers, D., Flexner, C., Siccardi, M., . . . Rannard, S. P. (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 10. doi:10.1038/s41467-019-09354-zDOI: 10.1038/s41467-019-09354-z
2018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro (Journal article)
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482DOI: 10.1021/acs.molpharmaceut.8b00482
Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens (Conference Paper)
Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Moss, D. M., Curley, P., Kinvig, H., Hoskins, C., & Owen, A. (2018). The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 12(3), 223-236. doi:10.1080/17474124.2018.1399794DOI: 10.1080/17474124.2018.1399794
Curley, P., Liptrott, N. J., & Owen, A. (2018). Advances in nanomedicine drug delivery applications for HIV therapy. FUTURE SCIENCE OA, 4(1). doi:10.4155/fsoa-2017-0069DOI: 10.4155/fsoa-2017-0069
Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens (Conference Paper)
Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/
Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage (Conference Paper)
Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
2017
Curley, P., Giardiello, M., Liptrott, N. J., Dickens, D., Moss, D. M., Hobson, J. J., . . . Owen, A. (2017). In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2(3), 157-169. doi:10.1002/jin2.32DOI: 10.1002/jin2.32
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16DOI: 10.1128/AAC.01841-16
Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot (Conference Paper)
Hobson, J., Curley, P., Al-khouja, A., Meyers, C., Flexner, C., Owen, A., & Rannard, S. (2017). Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
2016
Curley, P., Siccardi, M., Moss, D. M., & Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8(20), 2125-2134. doi:10.4155/bio-2016-0021DOI: 10.4155/bio-2016-0021
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21DOI: 10.1002/jin2.21
Handbook of Immunological Properties of Engineered Nanomaterials (Chapter)
Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677DOI: 10.1142/9677
Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery (Chapter)
Liptrott, N. J., Curley, P., Tatham, L. M., & Owen, A. (2016). Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. In Handbook of Immunological Properties of Engineered Nanomaterials (pp. 205-239). WORLD SCIENTIFIC. doi:10.1142/9789813140479_0009DOI: 10.1142/9789813140479_0009
2015
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry (Journal article)
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53DOI: 10.2217/pgs.15.53
2014
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312DOI: 10.1093/jac/dku312
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312DOI: 10.1093/jac/dku312
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation (Journal article)
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280DOI: 10.1002/adhm.201300280
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine (Poster)
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration (Poster)
Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs (Chapter)
Owen, A., & Curley, P. (2014). Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. In Humanized Mice for HIV Research (pp. 339-360). Springer New York. doi:10.1007/978-1-4939-1655-9_28DOI: 10.1007/978-1-4939-1655-9_28
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents (Poster)
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
2013
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225DOI: 10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i> (Journal article)
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13DOI: 10.1128/AAC.01421-13
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67DOI: 10.2217/fvl.13.67
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles (Conference Paper)
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach (Poster)
Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Presentation material)
Curley, P. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Amsterdam, Netherlands.
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Poster)
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Assessment of aqueous and nanoparticle antiretroviral drug transport in the blood brain barrier (Presentation material)
Curley, P. (2012). Assessment of aqueous and nanoparticle antiretroviral drug transport in the blood brain barrier. Liverpool, UK.
Investigation of the potential interactions of efavirenz with the GABAa receptor (Poster)
Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.
2009
An Investigation of the expression of cytochrome P450 3A7 and cytochrome P450 3A4 during stem cell differentiation for use as markers of emerging hepatic phenotype (Conference Paper)
Curley, P., Kelly, L., Shaw, R., Kitteringham, N., Jenkins, R., Alder, J., . . . Park, K. (2009). An Investigation of the expression of cytochrome P450 3A7 and cytochrome P450 3A4 during stem cell differentiation for use as markers of emerging hepatic phenotype. In British Pharmacology Society Winter Meeting. London, UK.
Undated
Curley, P. (n.d.). Understanding disposition of efavirenz and application in solid drug nanoparticle development. (PhD Thesis, University of Liverpool).